These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7490726)

  • 21. Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction.
    Riendeau D; Falgueyret JP; Guay J; Ueda N; Yamamoto S
    Biochem J; 1991 Feb; 274 ( Pt 1)(Pt 1):287-92. PubMed ID: 2001245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): studies in rats and 5-LO knockout mice.
    Beierschmitt WP; McNeish JD; Griffiths RJ; Nagahisa A; Nakane M; Amacher DE
    Toxicol Sci; 2001 Sep; 63(1):15-21. PubMed ID: 11509739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
    Machinist JM; Mayer MD; Shet MS; Ferrero JL; Rodrigues AD
    Drug Metab Dispos; 1995 Oct; 23(10):1163-74. PubMed ID: 8654206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nitroxide metabolites from alkylhydroxylamines and N-hydroxyurea derivatives resulting from reductive inhibition of soybean lipoxygenase.
    Chamulitrat W; Mason RP; Riendeau D
    J Biol Chem; 1992 May; 267(14):9574-9. PubMed ID: 1315759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
    Satoh Y; Stanton JL; Hutchison AJ; Libby AH; Kowalski TJ; Lee WH; White DH; Kimble EF
    J Med Chem; 1993 Nov; 36(23):3580-94. PubMed ID: 8246226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABT-761 (Abbott).
    Reid JJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):68-71. PubMed ID: 11527015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Hydroxycinnamic Acid Esters as Novel 5-Lipoxygenase Inhibitors That Affect Leukotriene Biosynthesis.
    Boudreau LH; Lassalle-Claux G; Cormier M; Blanchard S; Doucet MS; Surette ME; Touaibia M
    Mediators Inflamm; 2017; 2017():6904634. PubMed ID: 28680195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
    Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor.
    Machinist JM; Mayer MD; Roberts EM; Surber BW; Rodrigues AD
    Drug Metab Dispos; 1998 Oct; 26(10):970-6. PubMed ID: 9763401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
    Greco MN; Hageman WE; Powell ET; Tighe JJ; Persico FJ
    J Med Chem; 1992 Aug; 35(17):3180-3. PubMed ID: 1324317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aqueous stability of SB 210661: kinetics and primary degradation mechanisms of an N-hydroxyurea-containing 5-lipoxygenase inhibitor.
    McLoughlin M; Kearney AS; Palepu NR
    J Pharm Pharmacol; 1998 Feb; 50(2):127-32. PubMed ID: 9530978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton.
    Rao NL; Dunford PJ; Xue X; Jiang X; Lundeen KA; Coles F; Riley JP; Williams KN; Grice CA; Edwards JP; Karlsson L; Fourie AM
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
    Smith WG; Shaffer AF; Currie JL; Thompson JM; Kim S; Rao T; Isakson PC
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1332-8. PubMed ID: 8531100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor.
    Shirumalla RK; Sharma P; Dastidar SG; Paliwal JK; Kakar S; Varshney B; Singh Saini G; Sattigeri V; Salman M; Ray A
    Inflamm Res; 2008 Mar; 57(3):135-43. PubMed ID: 18369577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
    Hui KP; Taylor IK; Taylor GW; Rubin P; Kesterson J; Barnes NC; Barnes PJ
    Thorax; 1991 Mar; 46(3):184-9. PubMed ID: 1851340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.
    Campestre C; Tortorella P; Agamennone M; Preziuso S; Biasone A; Nuti E; Rossello A; Gallina C
    Eur J Med Chem; 2008 May; 43(5):1008-14. PubMed ID: 17719700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrinsic 5-lipoxygenase activity is required for neutrophil responsivity.
    Guidot DM; Repine MJ; Westcott JY; Repine JE
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8156-9. PubMed ID: 8058773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma.
    Payne AN; Jackson WP; Salmon JA; Nicholls A; Yeadon M; Garland LG
    Agents Actions Suppl; 1991; 34():189-99. PubMed ID: 1793063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucuronidation of zileuton (A-64077) by human hepatic microsomes.
    Sweeny DJ; Bouska J; Machinist J; Bell R; Carter G; Cepa S; Nellans HN
    Drug Metab Dispos; 1992; 20(2):328-9. PubMed ID: 1352229
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.